Nifty
:
23659.00
Sensex
:
75318.39
41.00 (0.17%)
117.54 (0.16%)
Nifty
Sensex
:
:
23659.00
75318.39
41.00 (0.17%)
117.54 (0.16%)

Alembic Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
58/99

BSE: 533573 | NSE: APLLTD

NSE BSE
752.35
20-May-2026
  • Open
  • High
  • Low
  • Previous Close
  •  751.1
  •  762.25
  •  736.55
  •  751.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  68947
  •  51589424.3
  •  1107.9
  •  635.8

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 14,795.31
  • 21.93
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 15,953.46
  • 1.59%
  • 2.61

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 69.74%
  • 0.16%
  • 6.86%
  • FII
  • DII
  • Others
  • 4.26%
  • 15.86%
  • 3.12%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.74
  • 4.35
  • 5.68

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -0.02
  • -7.49
  • 7.21

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -2.08
  • -12.15
  • 19.49

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.55
  • 29.64
  • 30.56

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.57
  • 3.22
  • 3.59

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.72
  • 17.08
  • 18.58

Earnings Forecasts:

(Updated: 16-05-2026)
Description
2024
2025
2026
2027
Adj EPS
34.69
41.18
49.39
58.74
P/E Ratio
21.69
18.27
15.23
12.81
Revenue
7418.6
8242.16
9078.99
10142.9
EBITDA
1190.45
1382.95
1602.74
1929.7
Net Income
672.47
808.68
970
1154.7
ROA
8.53
9.21
10.88
12.47
P/B Ratio
2.61
2.38
2.13
1.99
ROE
12.64
13.63
14.74
16.36
FCFF
451.92
533.58
665.77
4022.91
FCFF Yield
2.78
3.28
4.09
24.74
Net Debt
970.02
708.92
349.87
BVPS
288.06
316.68
353.4
378.51

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
1,847.72
1,769.64
4.41%
1,876.31
1,692.74
10.84%
1,910.15
1,647.98
15.91%
1,710.72
1,561.73
9.54%
Expenses
1,619.80
1,497.72
8.15%
1,582.81
1,432.52
10.49%
1,594.46
1,408.71
13.19%
1,429.38
1,324.90
7.89%
EBITDA
227.92
271.92
-16.18%
293.50
260.22
12.79%
315.69
239.27
31.94%
281.34
236.83
18.79%
EBIDTM
12.34%
15.37%
15.64%
15.37%
16.53%
14.52%
16.45%
15.16%
Other Income
25.50
14.19
79.70%
15.50
9.51
62.99%
6.91
16.74
-58.72%
6.50
2.10
209.52%
Interest
22.56
24.52
-7.99%
23.31
22.26
4.72%
24.23
18.81
28.81%
23.52
13.18
78.45%
Depreciation
88.59
68.99
28.41%
80.12
70.04
14.39%
76.07
70.51
7.89%
73.77
69.04
6.85%
PBT
117.51
192.60
-38.99%
163.34
177.43
-7.94%
222.30
179.56
23.80%
190.55
156.71
21.59%
Tax
-82.91
35.31
-
29.55
40.08
-26.27%
40.01
27.28
46.66%
36.47
22.49
62.16%
PAT
200.42
157.29
27.42%
133.79
137.35
-2.59%
182.29
152.28
19.71%
154.08
134.22
14.80%
PATM
10.85%
8.89%
7.13%
8.11%
9.54%
9.24%
9.01%
8.59%
EPS
10.31
7.98
29.20%
6.77
7.04
-3.84%
9.40
7.80
20.51%
7.85
6.85
14.60%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
7,344.90
6,672.08
6,228.63
5,652.62
5,305.78
5,393.14
4,605.76
3,934.69
3,130.81
3,134.61
3,165.99
Net Sales Growth
10.08%
7.12%
10.19%
6.54%
-1.62%
17.10%
17.06%
25.68%
-0.12%
-0.99%
 
Cost Of Goods Sold
1,984.45
1,793.36
1,715.08
1,708.82
1,446.43
1,257.35
1,039.38
992.71
886.19
887.57
823.95
Gross Profit
5,360.45
4,878.72
4,513.55
3,943.80
3,859.35
4,135.79
3,566.38
2,941.98
2,244.62
2,247.04
2,342.04
GP Margin
72.98%
73.12%
72.46%
69.77%
72.74%
76.69%
77.43%
74.77%
71.69%
71.68%
73.97%
Total Expenditure
6,226.45
5,669.16
5,296.00
4,944.56
4,431.64
3,913.05
3,391.69
3,078.87
2,515.55
2,519.90
2,160.88
Power & Fuel Cost
-
179.69
173.37
151.54
120.84
118.72
102.40
88.86
70.35
64.20
58.89
% Of Sales
-
2.69%
2.78%
2.68%
2.28%
2.20%
2.22%
2.26%
2.25%
2.05%
1.86%
Employee Cost
-
1,562.34
1,446.29
1,169.13
1,133.00
1,051.17
906.44
746.69
622.81
558.83
472.85
% Of Sales
-
23.42%
23.22%
20.68%
21.35%
19.49%
19.68%
18.98%
19.89%
17.83%
14.94%
Manufacturing Exp.
-
440.63
387.71
409.37
379.15
372.18
368.41
269.25
244.53
289.79
271.51
% Of Sales
-
6.60%
6.22%
7.24%
7.15%
6.90%
8.00%
6.84%
7.81%
9.24%
8.58%
General & Admin Exp.
-
576.40
525.84
492.64
413.90
391.24
339.82
340.56
283.43
299.79
233.28
% Of Sales
-
8.64%
8.44%
8.72%
7.80%
7.25%
7.38%
8.66%
9.05%
9.56%
7.37%
Selling & Distn. Exp.
-
1,064.86
996.88
952.30
890.38
687.41
531.19
590.28
380.21
393.14
274.14
% Of Sales
-
15.96%
16.00%
16.85%
16.78%
12.75%
11.53%
15.00%
12.14%
12.54%
8.66%
Miscellaneous Exp.
-
51.88
50.83
60.76
47.94
34.98
104.05
50.52
28.03
26.58
274.14
% Of Sales
-
0.78%
0.82%
1.07%
0.90%
0.65%
2.26%
1.28%
0.90%
0.85%
0.83%
EBITDA
1,118.45
1,002.92
932.63
708.06
874.14
1,480.09
1,214.07
855.82
615.26
614.71
1,005.11
EBITDA Margin
15.23%
15.03%
14.97%
12.53%
16.48%
27.44%
26.36%
21.75%
19.65%
19.61%
31.75%
Other Income
54.41
47.86
29.04
3.04
50.49
87.48
13.88
27.14
34.87
2.58
8.83
Interest
93.62
78.77
56.19
50.17
17.73
16.02
27.16
18.41
3.40
5.23
5.43
Depreciation
318.55
278.57
272.67
275.43
286.78
183.47
157.32
115.23
105.46
82.97
72.21
PBT
693.70
693.44
632.81
385.50
620.12
1,368.08
1,043.47
749.32
541.27
529.09
936.30
Tax
23.12
125.17
16.01
12.60
104.46
253.32
199.18
156.75
120.36
122.19
216.12
Tax Rate
3.33%
17.72%
2.53%
3.27%
16.85%
18.52%
19.92%
20.92%
22.24%
23.09%
23.08%
PAT
670.58
583.42
615.82
341.99
520.94
1,114.76
828.76
593.65
420.72
406.99
720.03
PAT before Minority Interest
674.52
582.01
615.82
341.99
520.94
1,114.76
800.64
592.57
420.91
406.90
720.03
Minority Interest
3.94
1.41
0.00
0.00
0.00
0.00
28.12
1.08
-0.19
0.09
0.00
PAT Margin
9.13%
8.74%
9.89%
6.05%
9.82%
20.67%
17.99%
15.09%
13.44%
12.98%
22.74%
PAT Growth
15.39%
-5.26%
80.07%
-34.35%
-53.27%
34.51%
39.60%
41.10%
3.37%
-43.48%
 
EPS
34.11
29.68
31.32
17.40
26.50
56.70
42.15
30.20
21.40
20.70
36.62

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
5,190.94
4,818.20
4,370.47
5,237.54
5,066.98
3,219.42
2,718.83
2,220.14
1,902.33
1,597.36
Share Capital
39.31
39.31
39.31
39.31
39.31
37.70
37.70
37.70
37.70
37.70
Total Reserves
5,151.63
4,778.89
4,331.16
5,198.23
5,027.67
3,181.72
2,681.13
2,182.44
1,864.63
1,559.66
Non-Current Liabilities
5.05
2.75
52.42
162.07
361.16
1,046.98
570.06
576.20
94.15
84.02
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
0.00
0.00
0.00
199.89
886.99
499.30
500.00
0.00
0.00
Long Term Provisions
124.31
109.51
106.20
95.82
85.52
74.51
52.03
40.76
57.22
28.23
Current Liabilities
2,514.27
1,520.28
1,640.80
1,830.59
1,533.26
1,954.22
1,663.65
1,267.18
813.96
944.19
Trade Payables
879.89
735.64
679.81
706.39
668.78
625.93
644.34
759.32
500.73
565.65
Other Current Liabilities
232.10
223.66
251.19
516.51
557.92
226.98
380.19
142.89
81.28
51.80
Short Term Borrowings
1,195.57
430.45
635.87
430.00
0.02
860.50
429.13
207.78
88.51
113.71
Short Term Provisions
206.71
130.53
73.93
177.69
306.54
240.81
209.99
157.19
143.44
213.03
Total Liabilities
7,708.84
6,341.23
6,063.69
7,230.20
6,961.40
6,191.66
4,951.75
4,063.83
2,810.55
2,625.57
Net Block
2,523.53
2,546.71
2,398.45
1,797.85
1,788.42
1,551.84
1,158.45
993.38
799.40
708.09
Gross Block
4,117.32
3,875.21
3,467.50
2,840.33
2,545.39
2,132.41
1,522.57
1,242.47
950.09
1,093.63
Accumulated Depreciation
1,593.79
1,328.50
1,069.05
1,042.48
756.97
580.57
364.12
249.09
150.69
385.54
Non Current Assets
3,519.12
3,197.39
3,149.80
4,255.37
4,056.96
3,526.30
2,820.02
2,116.31
1,316.80
917.30
Capital Work in Progress
837.23
524.36
601.28
2,304.24
2,182.53
1,846.18
1,551.23
1,010.15
396.28
92.52
Non Current Investment
127.21
93.02
96.33
118.40
49.31
17.62
48.76
41.64
49.88
53.43
Long Term Loans & Adv.
31.15
33.30
53.74
34.88
36.70
110.66
61.58
71.14
71.24
29.96
Other Non Current Assets
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
33.30
Current Assets
4,189.72
3,143.84
2,913.89
2,974.83
2,904.44
2,665.36
2,131.73
1,947.52
1,493.75
1,708.27
Current Investments
0.00
0.00
0.00
0.00
186.97
0.00
0.00
0.00
0.00
0.00
Inventories
2,288.14
1,643.54
1,475.27
1,609.70
1,486.15
1,187.54
967.27
733.93
632.75
569.79
Sundry Debtors
1,399.79
1,024.84
1,046.41
807.13
348.60
864.75
488.92
526.34
338.82
350.48
Cash & Bank
90.09
126.57
82.27
69.43
105.84
80.75
205.62
89.92
159.60
450.83
Other Current Assets
411.70
59.86
55.32
51.65
776.88
532.32
469.92
597.33
362.58
337.17
Short Term Loans & Adv.
342.52
289.03
254.62
436.92
698.21
504.22
451.71
569.84
355.02
330.08
Net Current Assets
1,675.45
1,623.56
1,273.09
1,144.24
1,371.18
711.14
468.08
680.34
679.79
764.08
Total Assets
7,708.84
6,341.23
6,063.69
7,230.20
6,961.40
6,191.66
4,951.75
4,063.83
2,810.55
2,625.57

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
87.96
803.20
723.94
552.35
1,463.38
449.15
811.97
312.42
328.55
947.65
PBT
707.18
631.83
354.59
625.39
1,368.08
999.82
749.32
541.27
529.09
936.31
Adjustment
373.53
286.87
487.61
417.75
102.42
278.28
117.57
87.12
83.06
69.45
Changes in Working Capital
-921.36
-95.65
-57.56
-367.36
238.30
-592.84
111.56
-180.85
-165.64
138.90
Cash after chg. in Working capital
159.35
823.05
784.64
675.78
1,708.80
685.26
978.45
447.54
446.51
1,144.66
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-71.39
-19.85
-60.70
-123.43
-245.42
-236.11
-166.48
-135.12
-117.96
-197.01
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-568.41
-320.61
-447.59
-371.97
-838.80
-731.63
-755.60
-884.38
-485.91
-306.80
Net Fixed Assets
-554.36
-340.93
994.77
-402.51
-1,311.53
-789.71
-630.35
-606.86
-121.60
-288.80
Net Investments
-32.88
2.59
-9.91
123.73
490.16
-326.86
-207.50
-195.85
-65.58
-4.13
Others
18.83
17.73
-1,432.45
-93.19
-17.43
384.94
82.25
-81.67
-298.73
-13.87
Cash from Financing Activity
443.72
-437.86
-261.96
-217.35
-597.42
154.85
59.03
502.63
-128.88
-224.30
Net Cash Inflow / Outflow
-36.73
44.73
14.39
-36.97
27.16
-127.63
115.40
-69.33
-286.24
416.55
Opening Cash & Equivalents
120.21
75.48
61.09
98.06
71.83
199.06
83.74
153.07
439.32
22.77
Closing Cash & Equivalent
83.48
120.21
75.48
61.09
98.06
71.84
199.07
83.74
153.08
439.32

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
264.10
245.14
222.36
266.47
257.80
170.79
144.24
117.78
100.92
84.74
ROA
8.28%
9.93%
5.15%
7.34%
17.22%
14.64%
13.15%
12.25%
14.97%
33.76%
ROE
11.63%
13.40%
7.12%
10.11%
26.91%
26.97%
24.00%
20.42%
23.25%
58.03%
ROCE
13.51%
13.42%
7.44%
11.25%
26.28%
23.30%
22.66%
22.15%
28.87%
65.87%
Fixed Asset Turnover
1.67
1.70
1.79
1.97
2.31
2.52
2.85
2.86
3.07
3.24
Receivable days
66.32
60.69
59.84
39.75
41.06
53.64
47.09
50.43
40.13
41.02
Inventory Days
107.54
91.38
99.60
106.49
90.48
85.38
78.91
79.67
70.01
54.91
Payable days
164.40
150.62
148.04
173.51
187.92
69.87
88.23
98.47
84.03
80.04
Cash Conversion Cycle
9.46
1.45
11.40
-27.27
-56.39
69.15
37.76
31.63
26.12
15.89
Total Debt/Equity
0.23
0.09
0.15
0.12
0.10
0.54
0.42
0.32
0.05
0.07
Interest Cover
9.98
12.24
8.07
36.27
86.40
37.81
41.70
160.20
102.16
173.43

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Alembic Pharma - Quarterly Results
    16th May 2026, 00:00 AM

    Read More
  • Alembic Pharmaceuticals gets EIR from USFDA for Injectable facility in Gujarat
    14th May 2026, 12:10 PM

    The USFDA had conducted an unannounced cGMP inspection from February 9, 2026 to February 18, 2026

    Read More
  • Alembic Pharmaceuticals gets USFDA’s tentative nod for Darolutamide Tablets
    14th May 2026, 11:18 AM

    The approved ANDA is therapeutically equivalent to the reference listed drug product, Nubeqa Tablets, 300 mg, of Bayer

    Read More
  • Alembic Pharmaceuticals gets USFDA’s final approval for Fingolimod Capsules
    25th Apr 2026, 15:45 PM

    Alembic has a cumulative total of 237 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals incorporates wholly owned subsidiary in Germany
    23rd Apr 2026, 15:29 PM

    The objective of incorporation is to explore new business opportunities in this geography to promote, sale and distribute pharmaceuticals product(s) of the company

    Read More
  • Alembic Pharmaceuticals incorporates subsidiary in Philippines
    23rd Apr 2026, 09:59 AM

    The company has incorporated a subsidiary to explore new business opportunities in this geography to promote, sale and distribute pharmaceuticals product(s) of the company

    Read More
  • Alembic Pharmaceuticals gets USFDA’s final nod for Methotrexate Injection
    16th Apr 2026, 12:11 PM

    Alembic has a cumulative total of 236 ANDA approvals from USFDA

    Read More
  • Alembic Pharmaceuticals secures USFDA’s final approval for ‘Dapagliflozin Tablets’
    7th Apr 2026, 12:59 PM

    The company is eligible for 180 days of shared generic drug exclusivity

    Read More
  • Alembic Pharma gets USFDA’s final nod for Paroxetine Extended-Release Tablets
    27th Mar 2026, 17:46 PM

    The approved sANDA is therapeutically equivalent to the reference listed drug product, Paxil CR Tablets, 12.5 mg, of Apotex Inc

    Read More
  • Alembic Pharmaceuticals incorporates subsidiary in Thailand
    10th Mar 2026, 10:06 AM

    The Company holds 99.99% stake in Alembic Pharmaceuticals (Thailand) Co

    Read More
  • Alembic Pharma gets USFDA’s final approval for Lamotrigine Orally Disintegrating Tablets
    26th Feb 2026, 12:29 PM

    Alembic has a cumulative total of 235 ANDA approvals from USFDA

    Read More
  • Alembic Pharma gets USFDA’s final approval for Efinaconazole Topical Solution
    24th Feb 2026, 16:00 PM

    Alembic was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification

    Read More
  • Alembic Pharmaceuticals receives two observations for Karakhadi Injectable Facility
    19th Feb 2026, 16:44 PM

    The USFDA has conducted an unannounced cGMP inspection at the said facility from February 9, 2026 to February 18, 2026

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.